RT Journal Article
SR Electronic
T1 Late Breaking Abstract - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis (FITNESS study)
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP RCT2905
DO 10.1183/13993003.congress-2021.RCT2905
VO 58
IS suppl 65
A1 Ogura, Takashi
A1 MORI, YOSHIHIRO
A1 Kataoka, Kensuke
A1 Nishiyama, Osamu
A1 Ando, Masahiko
A1 Arizono, Shinichi
A1 Ogawa, Tomoya
A1 Shiraki, Akira
A1 Ichikado, Kazuya
A1 Ishimoto, Hiroshi
A1 Ito, Hiroyuki
A1 Sakamoto, Koji
A1 Tomii, Keisuke
A1 Tomioka, Hiromi
A1 Tsuda, Toru
A1 Kozu, Ryo
A1 Kondoh, Yasuhiro
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/RCT2905.abstract
AB Background: Pulmonary rehabilitation (PR) causes short-term improvement in exercise capacity, in IPF, but long-term maintenance is difficult. Nintedanib has been shown to slow the worsening of pulmonary function in IPF. The concomitant use of nintedanib with PR may contribute to the long-term maintenance of PR effects.Methods: This is a multicenter, randomized, prospective, parallel-group, open-label trial. Patients in the PR group will receive a programmed short-term PR induction, followed by home-based PR maintenance. Patients in the control group will receive usual outpatient care. Patients in both groups will continue to receive nintedanib. The primary endpoint is the change in the 6-minute walk distance (6MWD) from baseline to 12-months in the two groups. The main secondary endpoint is the change in endurance exercise time, measured using a bicycle ergometer.Results: Of the 88 randomized subjects, 74 completed the study (PR group n=38, control group n=36). In the primary-endpoint analysis, the change in 6MWD was -24 m in the PR group and -37 m in the control group (p=0.1502). In the main secondary-endpoint analysis, the change in endurance time was 93 sec in the PR group and -99 sec in the control group (p=0.0032).Conclusions: A long-term PR program in combination with nintedanib in patients with IPF did not improve 6MWD but did improve endurance exercise time.Acknowledgment: This study was supported by Boehringer Ingelheim.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, RCT2905.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).